Cencora Reports 5.1% Revenue Growth to $84.8 Million in Q3 Fiscal 2026

Cencora, Inc. reported a notable increase in its financial performance for the third quarter of fiscal 2026, with revenues reaching $84.8 million, a 5.1% increase from $80.7 million in the same quarter of the previous year. For the nine-month period ending June 30, 2026, total revenue was $249.0 million, up 4.8% from $237.6 million year-over-year. The company's net income for the quarter was $776.7 million, translating to earnings per share of $3.95, compared to $689.7 million and $3.55 per share in the prior year. The nine-month net income also saw a significant rise to $2.97 billion from $1.90 billion, reflecting a strong operational performance.

The company experienced substantial growth in its U.S. Healthcare Solutions segment, which reported a revenue increase of $3.5 billion, or 4.9%, for the quarter, driven by higher sales of specialty products and a notable 25.5% increase in sales of diabetes and weight loss products. The International Healthcare Solutions segment also contributed to the growth, with a revenue increase of 5.9% for the quarter, primarily due to enhanced sales in the European distribution business. However, the company faced challenges, including a decline in manufacturer prices for certain brand pharmaceuticals and reduced sales from specific customers.

Strategically, Cencora has made significant acquisitions, including the purchase of OneOncology in February 2026 for approximately $7.39 billion, which is expected to enhance its relationships with community oncology providers. The acquisition of Retina Consultants of America (RCA) in January 2025 for $4.04 billion also contributed to the company's growth. These acquisitions have been pivotal in expanding Cencora's market presence and operational capabilities. The company has also restructured its reporting segments to better align with its growth priorities, now categorizing its operations into U.S. Healthcare Solutions, International Healthcare Solutions, and Other.

Operationally, Cencora's total assets increased to $83.8 billion as of June 30, 2026, up from $76.6 billion a year earlier. The company reported a total employee headcount of 190,827 as of July 31, 2026. The increase in cash and cash equivalents was notable, with a decrease to $2.8 billion from $4.4 billion, reflecting the impact of acquisitions and operational expenditures. The company also reported a significant increase in its debt levels, with total debt rising to $11.7 billion, up from $7.7 billion, primarily due to financing activities related to its acquisitions.

Looking ahead, Cencora anticipates continued revenue growth driven by market trends, including the increasing demand for specialty pharmaceuticals and the introduction of new therapies. However, the company remains cautious about potential challenges, including economic conditions, pricing pressures, and regulatory changes that could impact its operations. The management has expressed confidence in its strategic direction and operational capabilities, aiming to leverage its recent acquisitions to enhance its market position and drive future growth.